Zobrazeno 1 - 10
of 1 839
pro vyhledávání: '"Ignacio I. Wistuba"'
Autor:
Alejandra G. Serrano, Pedro Rocha, Cibelle Freitas Lima, Allison Stewart, Bingnan Zhang, Lixia Diao, Junya Fujimoto, Robert J. Cardnell, Wei Lu, Khaja Khan, Beate Sable, Aaron R. Ellison, Ignacio I. Wistuba, Kyle F. Concannon, Daniel M. Halperin, Czerniak Bogdan, Kanishka Sircar, Miao Zhang, Kasey Cargill, Qi Wang, Ana Aparicio, Alexander Lazar, Sharia Hernandez, Jeannelyn Estrella, Preetha Ramalingam, Adel El-Naggar, Neda Kalhor, Carl M. Gay, Lauren Averett Byers, Luisa M. Solis Soto
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract Delta-like Ligand 3 (DLL3) targeting therapies are promising in small cell lung cancer (SCLC) treatment. However, DLL3 expression in SCLC and other neuroendocrine neoplasms (NEN) is heterogeneous and not well characterized. We describe the l
Externí odkaz:
https://doaj.org/article/ff8fbd20faf44861bff7caa2e497764c
Autor:
Chenyang Li, Thinh T. Nguyen, Jian-Rong Li, Xingzhi Song, Junya Fujimoto, Latasha Little, Curtis Gumb, Chi-Wan B. Chow, Ignacio I. Wistuba, Andrew P. Futreal, Jianhua Zhang, Shawna M. Hubert, John V. Heymach, Jia Wu, Christopher I. Amos, Jianjun Zhang, Chao Cheng
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-14 (2024)
Abstract Lung Cancer remains the leading cause of cancer deaths in the USA and worldwide. Non-small cell lung cancer (NSCLC) harbors high transcriptomic intratumor heterogeneity (RNA-ITH) that limits the reproducibility of expression-based prognostic
Externí odkaz:
https://doaj.org/article/b6fe0a65261748579d8ae587987a1d01
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract The tumor microenvironment (TME) plays a fundamental role in tumorigenesis, tumor progression, and anti-cancer immunity potential of emerging cancer therapeutics. Understanding inter-patient TME heterogeneity, however, remains a challenge to
Externí odkaz:
https://doaj.org/article/38900c22a8a24e709b0c4f0b13cb9893
Autor:
Ignacio I Wistuba, Amelia Insa, Mariano Provencio, Bartomeu Massutí, Federico Garrido, Edwin R Parra, Delvys Rodriguez-Abreu, Manuel Cobo, Joaquín Casal-Rubio, Ernest Nadal, Javier Martín-López, Diego Megías, Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Alex Martinez-Marti, Isidoro Barneto Aranda, Santiago Viteri, Marta Casarrubios, Cristina Martinez-Toledo, Virginia Calvo, Marta Molina-Alejandre, Francisco Perea, Javier de Castro, Joaquín Mosquera Martínez, Rafael Muñoz-Viana, Natalia Aptsiauri, Francisco Ruiz-Cabello
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to immunotherapy. However, there is no data on periopera
Externí odkaz:
https://doaj.org/article/8c3f29b6cb394ac3ba9e2fc1ab852402
Autor:
Daowei Yang, Xinlei Sun, Rohan Moniruzzaman, Hua Wang, Citu Citu, Zhongming Zhao, Ignacio I. Wistuba, Huamin Wang, Anirban Maitra, Yang Chen
Publikováno v:
Cell Reports Medicine, Vol 5, Iss 9, Pp 101711- (2024)
Summary: Pancreatic cancer is associated with an oncogenic KRAS mutation in approximately 90% of cases. However, a non-negligible proportion of pancreatic cancer cases harbor wild-type KRAS (KRAS-WT). This study establishes genetically engineered mou
Externí odkaz:
https://doaj.org/article/86f14644049346438d351b6697eb089c
Autor:
Mabel Perez-Oquendo, Gabriele Romano, David P. Farris, Varsha Gandhi, Ignacio I. Wistuba, Robert E. Tillman, Ryan Udan, Paolo Mangahas, Rama Soundararajan
Publikováno v:
BMC Medical Education, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract The United States government makes a substantial investment in biomedical training programs each year. However, for most trainees, these opportunities do not translate into career progression in academic research pathways. Only about one-fif
Externí odkaz:
https://doaj.org/article/5cff586dbc0344188e10aa42c9cb42e6
Autor:
Sheeba J. Sujit, Muhammad Aminu, Tatiana V. Karpinets, Pingjun Chen, Maliazurina B. Saad, Morteza Salehjahromi, John D. Boom, Mohamed Qayati, James M. George, Haley Allen, Mara B. Antonoff, Lingzhi Hong, Xin Hu, Simon Heeke, Hai T. Tran, Xiuning Le, Yasir Y. Elamin, Mehmet Altan, Natalie I. Vokes, Ajay Sheshadri, Julie Lin, Jianhua Zhang, Yang Lu, Carmen Behrens, Myrna C. B. Godoy, Carol C. Wu, Joe Y. Chang, Caroline Chung, David A. Jaffray, Ignacio I. Wistuba, J. Jack Lee, Ara A. Vaporciyan, Don L. Gibbons, John Heymach, Jianjun Zhang, Tina Cascone, Jia Wu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract While we recognize the prognostic importance of clinicopathological measures and circulating tumor DNA (ctDNA), the independent contribution of quantitative image markers to prognosis in non-small cell lung cancer (NSCLC) remains underexplor
Externí odkaz:
https://doaj.org/article/8ee2d864530b4ff5bcd6763fb81cd4af
Autor:
Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Rationale of the trial Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We i
Externí odkaz:
https://doaj.org/article/6a562891133f4ee084b42c34b2d77b3e
Autor:
Jose A. Karam, Pavlos Msaouel, Cara L. Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita, Amishi Y. Shah, Ignacio I. Wistuba, Enrica Marmonti, Dzifa Y. Duose, Edwin R. Parra, Luisa Maren Solis Soto, Caddie Laberiano-Fernandez, Marisa Lozano, Alice Abraham, Max Hallin, Curtis D. Chin, Peter Olson, Hirak Der-Torossian, Xiaohong Yan, Nizar M. Tannir, Christopher G. Wood
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Abstract Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in
Externí odkaz:
https://doaj.org/article/8affada371c5430f97f977800c38a734
Autor:
Raphael E. Steiner, Edwin R. Parra, Francisco Vega, Lei Feng, Jason R. Westin, Sattva S. Neelapu, Paolo Strati, Michael R. Green, Christopher R. Flowers, Luisa M. Solis, Ignacio I. Wistuba, Sairah Ahmed, Ranjit Nair, Fredrick B. Hagemeister, Mansoor Noorani, Mario L. Marques-Piubelli
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-5 (2023)
Abstract Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy, p
Externí odkaz:
https://doaj.org/article/e3114eba62f94495bc871889c61eb0f9